6-mercaptopurine
Selected indexed studies
- 6-Mercaptopurine and Macrophage Activation Syndrome Case Report and Review of the Literature. (J Pharm Pract, 2023) [PMID:35341387]
- Why more 6-mercaptopurine? (Semin Hematol, 1991) [PMID:1780746]
- Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. (World J Gastroenterol, 2011) [PMID:22072847]
_Worker-drafted node — pending editorial review._
Connections
6-mercaptopurine is a side effect of
Sources
- Why more 6-mercaptopurine? (1991) pubmed
- The clinical pharmacology of 6-mercaptopurine. (1992) pubmed
- The genetic toxicology of 6-mercaptopurine. (1993) pubmed
- 6-mercaptopurine. (1981) pubmed
- 6-Mercaptopurine dosage. (1987) pubmed
- 6-Mercaptopurine and Macrophage Activation Syndrome Case Report and Review of the Literature. (2023) pubmed
- Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. (2011) pubmed
- 6-Mercaptopurine in maintaining remission in Crohn's disease: An old friend becomes a new hero. (2000) pubmed
- Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. (2004) pubmed
- Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability. (2023) pubmed